Pfizer (PFE), Medivation (MDVN) Report Dimebon Does Not Report Statistically Significant Results in Phase 3 HORIZON
Tweet
Share
E-mailGet Alerts PFE Hot Sheet
Join SI Premium – FREE
Pfizer Inc (NYSE: PFE) and Medivation, Inc. (Nasdaq: MDVN) report the following results from the Phase 3 HORIZON trial of the investigational drug dimebon (latrepirdine*) in patients with Huntington disease.
Dimebon did not achieve statistical significance for either of the co-primary endpoints, the Mini-Mental State Examination (MMSE), which measures cognition (p=0.39), or the Clinician's Interview-Based Impression of Change, plus caregiver input (CIBIC-plus), which measures global function (p=0.84).
Dimebon did not achieve statistical significance for either of the co-primary endpoints, the Mini-Mental State Examination (MMSE), which measures cognition (p=0.39), or the Clinician's Interview-Based Impression of Change, plus caregiver input (CIBIC-plus), which measures global function (p=0.84).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves Regeneron's Pasatru for rare bone disorder FOP
- Cleveland-Cliffs plans $1B upgrade at Middletown Works steel plant
- Synaptics CFO resigns amid pending ON Semiconductor merger
Create E-mail Alert Related Categories
Corporate News, FDA, Hot FDA News, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
